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Abstract
CD4+CD25+ regulatory T cells (Treg) are important mediators of immune tolerance. A subset of Treg can be generated in
the periphery by TGF-beta dependent conversion of conventional CD4+CD252 T cells into induced Treg (iTreg). In chronic
viral infection or malignancy, such induced iTreg, which limit the depletion of aberrant or infected cells, may be of
pathogenic relevance. To identify potential targets for therapeutic intervention, we investigated the TGF-beta signaling in
Treg. In contrast to conventional CD4+ T cells, Treg exhibited marked activation of the p38 MAP kinase pathway. Inhibition
of p38 MAP kinase activity prevented the TGF-beta-dependent conversion of CD4+CD252 T cells into Foxp3+ iTreg in vitro.
Of note, the suppressive capacity of nTreg was not affected by inhibiting p38 MAP kinase. Our findings indicate that
signaling via p38 MAP kinase seems to be important for the peripheral generation of iTreg; p38 MAP kinase could thus be a
therapeutic target to enhance immunity to chronic viral infection or cancer.
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Introduction
CD4+CD25+ Treg are crucial for the maintenance of
peripheral immune tolerance and the prevention of chronic
inflammation and autoimmune disease [1]. In vivo, the majority of
the CD4+CD25+ Treg pool is generated in the thymus (natural or
nTreg) [2]; but a significant proportion of CD4+CD25+ Treg
seems to be generated in the periphery (induced or iTreg)
[3,4,5,6,7,8]. Cancer cells, as well as certain viruses are believed to
take advantage of this process in that they induce CD4+CD25+
Treg in the periphery, which suppress the efficient elimination of
infected or aberrant cells [9,10,11,12]. Therefore, manipulation of
this process could help to activate immunity to virus or cancer.
We hypothesized that interference with TGF-beta signaling could
be a possible way to manipulate the peripheral generation of iTreg.
TGF-beta is a pleiotropic cytokine with a prominent role in the
homeostatic regulation of the immune system [13]. While the thymic
generation of nTreg occurs independently from TGF-beta [14,15],
there is accumulating evidence that TGF-beta promotes the
expansion of the peripheral Treg pool in vivo [5], either through
direct expansion of precommitted nTreg [10,15,16], or through the
conversion of conventional CD4+CD252 Tc e l l si n t oF o x p 3 -
expressing iTreg [3,4,6,8]. This process seems to depend on Smad3
activation [17]. Furthermore, TGF-beta signaling has been reported
to be important for the suppressive function of nTreg [14,15].
To identify the relevant signaling pathways involved in the
TGF-beta–induced peripheral generation of iTreg, we here
assessed Smad and p38 signaling in murine nTreg and iTreg.
Upon binding of TGF-beta to type II and recruitment of type I
receptors the major TGF-beta signal is transmitted by Smad
proteins. Smad 2 and/or Smad 3 are being phosphorylated and
form a complex with Smad 4, which then translocates to the
nucleus in order to modulate the expression of TGF-beta
regulated genes [13]. Alternatively, TGF-beta may induce
activation of p38 MAP kinase through a Smad-independent
signaling pathway [18]. The p38 MAP kinase belongs to the family
of MAP kinases, which also includes ERK-1/2 and JNK [19].
Since mice deficient in p38 exhibit embryonic lethality [20], most
analyses of p38 function in lymphocytes have relied on the use of
pharmacologic inhibitors, such as SB203580 [21].
Materials and Methods
Animals
For all experiments age-matched FVB/N mice were used.
Animal care was in accordance with the governmental and
institutional guidelines. Approval was given by the local institu-
tional committee (‘Beho ¨rde fu ¨r Soziales, Familie, Gesundheit und
Verbraucherschutz, Freie und Hansestadt Hamburg, Nr. 97/06’).
Lymphocyte separation, cell culture and cell proliferation
assays
The isolation of CD4+CD252 and CD4+CD25+ T cells from
the spleens of 7 to 8 weeks old FVB/N mice by MACS and FACS
was performed essentially as described [15,22]. For the conversion
of CD4+CD252 T cells into iTreg, CD4+CD252 T cells were
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soluble CD28 mAb (BD, Heidelberg, Germany) in the presence of
2 ng/ml hTGF-beta1 (R&D Systems, Mineapolis, MN). The
expression of Foxp3 and CD25 was assessed by flow cytometry as
a marker of conversion. To test the suppressive capacity of nTreg
or iTreg, freshly isolated CD4+CD252 T cells from spleen of wild
type animals as responder cells were labelled with CFSE (2 mM,
5 min.; 5-,6- carboxyfluorescein diacetate, succinimidyl ester;
Molecular Probes, Leiden, The Netherlands), and stimulated with
allogeneic, irradiated APC and soluble CD3 mAb (3 mg/ml) for 4
days in the presence or absence of nTreg or the whole cell
suspension gained by in vitro conversion assays at ratios indicated
(responder+suppressor610
5). CFSE dilution as a marker for
proliferation was measured using flow cytometry. SB203580,
SB202190, or SP600125 (all 10 mM) or PD98059 (50 mM) in 10%
DMSO/PBS was added to the culture medium every 12 h (all
from Calbiochem, Darmstadt, Germany). DMSO was added to
control cultures at equivalent concentrations.
Flow cytometry
For flow cytometric analyses, cells were stained with Foxp3-PE/
APC (eBioscience, San Diego, CA) and CD25 FITC (BD)
according to the manufacturers instructions. Flow cytometry was
performed with a FACSCalibur using CellQuest software or with
a FACSCanto (BD Biosciences). At least 1610
4 cells were
analyzed.
Western blot analysis
Cell lysates were prepared by homogenization of snap frozen
cell pellets in PBS containing 1% TritonX-100 supplemented with
NaF (10 mM), EDTA (2 mM), benzamidine (10 mM), PMSF
(1 mM), leupeptin (1 mg/ml), Na3VO4 (2 mM) and aprotinin
(1,5 mg/ml). Protein content was measured by Bradford-Assay and
10 mg total protein was loaded onto 12% SDS/Page. Proteins
were blotted onto nitrocellulose membranes (Schleicher&Schuell,
Dassel, Germany), blocked in 5% dry non-fat milk and probed
with primary antibodies and appropriate HRP-conjugated sec-
ondary antibodies. Detection was performed using an ECL kit
(Roth, Karlsruhe, Germany).
All chemicals were purchased from Sigma (St. Louis, IL, USA),
if not otherwise stated. All antibodies were purchased from Cell
Signaling (Danvers, MA, USA), except for p-Erk and Actin (Santa
Cruz, CA, USA), Smad7 (R&D Systems, Minneapolis, MN, USA)
and FoxP3 (eBioscience, San Diego, CA). Secondary HRP-
conjugated anti-mouse and anti-rabbit antibodies were supplied
by Cell Signaling (Danvers, MA, USA).
Statistical analysis
Values are presented as mean +/2 SEM per group. The non-
parametric Mann-Whitney U test was used and a p,0.05
considered as significant. SPSS statistical software (SPSS inc.,
Chicago, USA) was used for analysis.
Results
Increased activity of the p38 MAP kinase pathway in
freshly isolated CD4+CD25+ T cells
To analyze which of the possible TGF-beta-induced signaling
pathways may be of relevance for Treg in vivo, we studied the
phosphorylation of Smad 2/3 and p38, ERK or JNK MAP kinases
in freshly isolated murine CD4+CD25+ and CD4+CD252 T cells.
The amounts of p38 MAP kinase appeared to be similar both in
CD4+CD25+ and CD4+CD252 T cells (Figure 1A; WT).
However, the phosphorylation of p38 MAP kinase in
CD4+CD25+ T cells was strongly increased as compared to
CD4+CD252 T cells (Figure 1A; WT). Of note, the phosphor-
ylation of p38 MAP kinase was decreased in transgenic
CD4+CD25+ T cells that overexpress a dominant negative
TGFbeta type II receptor, indicating at least partial TGF-beta-
dependence of the p38 signal (Figure 1A; TG). We did not find
any significant differences in the phosphorylation of JNK or ERK
between freshly isolated CD4+CD252 and CD4+CD25+ T cells
(Figure 1B). As compared to CD4+CD252 T cells, the
phosphorylation of Smad 2 and Smad 3 was increased whereas
the inhibitory Smad 7 was found to be strongly downregulated in
CD4+CD25+ T cells (Figure 1 B+C). In order to adjust for
potential differences in the amount of Smad 2- or 3-expression, we
determined the ratio of phosphorylated to unphosphorylated
protein in four independent experiments, and found that
activation of Smad 2 and 3 and of p38 was significantly increased
in the CD4+CD25+ T cells, as compared to the CD4+CD252 T
cells (Figure 1C).
Figure 1. Western blot analysis of MAP kinase and Smad
phosphorylation in CD4+CD252 and CD4+CD25+ T cells (2–
4610
6 cells). A: Analysis of p38 and ERK2 expression as well as p38
phosphorylation in CD4+CD252 and CD4+CD25+ T cells freshly isolated
from spleen of wild type mice or transgenic mice overexpressing a
dominant negative TGF-beta type II receptor in T cells. B: Analysis of
Smad 2/3, Smad 7, Foxp3, actin, p-Smad 2, p-Smad 3, p-JNK and p-
ERK1/2 from CD4+CD252 and CD4+CD25+ T cells freshly isolated from
spleen of wild type animals. C: Densitometry and ratio of phosphor-
ylated to unphosphorylated p38 and Smad 2/3 (p,0.05). The
experiments were at least repeated three times giving similar results.
doi:10.1371/journal.pone.0003302.g001
p38 MAP Kinase and Treg
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inhibition of this signaling blocks the conversion of
CD4+CD252 T cells into Foxp3-expressing, TGF-beta-
induced iTreg in vitro
It has been shown that TGF-beta1 induces Foxp3 transcription
in peripheral naı ¨ve CD4 T cells [3]. This conversion to iTreg
seems to depend on Smad 3 activation [17]. We therefore first
analyzed TGF-beta1 signaling pathways in freshly isolated
CD4+CD252 T cells. In the absence of activating signals and
TGF-beta1, spontaneous activation of p38 MAP kinase as well as
Smad 3 was observed (Figure S 1), which may have been caused
by the isolation procedure and/or cytokines carried over into the
culture. The spontaneous Smad 3 activation lasted for at least
2 hours, that of p38 lasted for at least 4 hours (Figure S 1).
Addition of TGF-beta1 in the absence of activating signals
induced the activation of both Smad 3 and p38, detectable at
4 hours and 16 hours of culture (Figure 2). At 16 hours, but not at
4 hours of culture, T cell activation by CD3 and CD28 antibody
enhanced the TGF-beta1-induced p38 and Smad 3 activation
(Figure 2). T cell activation in the absence of TGF-beta1 did not
induce Smad 3 activation, but p38 phosphorylation, weakly at
4 hours and strongly at 16 hours of culture (Figure 2). Thus, in
addition to Smad signaling, TGF-beta1 seemed to induce early
p38 activation, detectable at 4 hours of culture (Figure 2).
We therefore next analyzed the role of p38 MAP kinase
signaling for the conversion of CD4+CD252 T cells into Foxp3-
expressing iTreg in vitro (Figure 3A). CD4+CD252 T cells were
cultured for four days in the presence or absence of TGF-beta1.
The role of p38 signaling was investigated by adding the specific
p38 inhibitors SB203580 or SB202190 to the cultures twice daily.
Alternatively, ERK inhibitor PD98059 or JNK inhibitor
SP600125 was added to the culture. The rates of conversion into
iTreg were determined by flow cytometric analysis of Foxp3-
expression and assessment of the functional suppressive activity of
the induced cells in vitro (Figure 3B).
In the absence of inhibitor, CD4+CD252 T cells cultured with
TGF-beta1 acquired suppressive function and showed an
increased Foxp3-expression (Figure 3B). In contrast, the presence
of either p38 inhibitor dose-dependently blocked the TGF-beta-
induced conversion into iTreg, as seen by a reduced suppressive
activity and Foxp3-expression (Figure 3B). A representative
analysis of CD252 and Foxp3-expression after the TGF-beta
induced in vitro conversion in the presence or absence of the
inhibitor SB203580 is shown in Figure 4. The inhibitor did not
compromise viability of the cells, as determined by staining with
propidium iodide (91.5% negative with inhibitor vs. 90.5%
negative without inhibitor), and similar cell numbers could be
obtained after culture (on average 6.8610
5 with TGF-beta1 and
inhibitor vs. 7.1610
5 with TGF-beta1 and without the inhibitor).
At higher concentrations than used in our experiments, the p38
inhibitors have been reported to inhibit other MAP kinases
[21,23]. To exclude that the blockade of Foxp3-induction by the
p38 inhibitor was not mediated by p38, but other MAP kinases, we
Figure 2. TGF-beta1 activates Smad 3 and p38 MAP kinase in
CD4+CD252 T cells. Freshly isolated CD4+CD252 T cells (4610
6)
were cultured with or without TGF-beta1 for 4 or 16 hours. Cells were
activated with plate bound anti-CD3 mAb (2 mg/ml) and soluble anti-
CD28 mAb (2 mg/ml) as indicated. Smad 3 and p38 activation were
measured using Western blot. The experiments were repeated three
times giving similar results.
doi:10.1371/journal.pone.0003302.g002
Figure 3. Signaling via p38 MAP kinase is required for the in
vitro conversion of CD4+CD252 T cells into TGF-beta1-
induced Foxp3+ Treg (Ti Treg). CD4+CD252 T cells were activated
with plate bound anti-CD3 mAb (2 mg/ml) and soluble anti-CD28 mAb
(2 mg/ml) for 4 days in the presence or absence of TGF-beta1 (2 ng/ml).
Kinase inhibitors were added every 12 h (SB203580 (10 mM), SP600125
(10 mM), PD89059 (50 mM)). A: Schematic experimental procedure. Ti
Treg: TGF-beta-induced Treg. B: Foxp3-expression and in vitro
suppressor assay using CD4+CD252 CFSE-labelled responder T cells
isolated from spleen and suppressor T cells generated by in vitro
conversion as described above. Cells were washed three times before
adding to the culture. Responder and suppressor cells were added at
the indicated ratios [610
5]. Data are representative of three indepen-
dent experiments using SP600125, PD89059, SB202190 and five
independent experiments using SB203580.
doi:10.1371/journal.pone.0003302.g003
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However, these inhibitors had no effect on the conversion of
CD4+CD252 T cells into Foxp3+ iTreg (Figure 3B).
To further confirm the specificity of inhibition by the inhibitor
SB203580 and the control inhibitors of JNK (SP600125) and ERK
(PD98059), we analysed the activities of the p38, JNK and ERK
pathways during in vitro conversion into iTreg (Figure 5A). We
found that the p38 inhibitor SB203580 selectively blocked the
phosphorylation of MAPKAP2, which is a downstream target of
p38 MAP kinase (Figure 5A). Accordingly, PD98059 blocked the
phosphorylation of ERK, but not MAPKAP2. The JNK pathway
seemed to be only minimally activated in vitro (data not shown)
and we could therefore not detect any phosphorylation of the JNK
downstream target c-jun, making it difficult to prove a selective
effect of SP600125 on the JNK pathway (Figure 5A). Of note, the
p38 inhibitor SB203580 did not block Smad signaling, but rather
seemed to induce Smad 3 activation itself (Figure 5B).
p38 MAP kinase signaling is not required for the
suppressive function of nTreg in vitro
The above findings indicate that p38 MAP kinase could be a
therapeutic target for preventing the peripheral generation of
iTreg in the context of malignancies or chronic viral infection.
However, a complete inhibition of Treg suppressive function could
have adverse effects and induce autoimmune disease. We therefore
tested whether p38 inhibition may inhibit the suppressive function
of nTreg. To that end, the p38 inhibitor SB203580 was added to
an in vitro suppressor assay twice daily (Figure 6). We did not find
a significant difference in the suppressive capacity of nTreg with or
without p38 inhibitor (1+1, % of undivided cells: 54% (DMSO) vs.
50% (SB203580)). Similar results were obtained using another p38
MAP kinase inhibitor (SB202190, not shown). These findings
indicate that the in vitro suppressive function of established nTreg
is not blocked by inhibition of the p38 MAP kinase pathway.
Figure 4. Converted cells express CD25 and Foxp3 and are functional in vitro. A: Representative CD25-/Foxp3-expression after in vitro
conversion into iTreg in the presence or absence of SB203580. B: In vitro suppressor assay using CD4+CD252 CFSE-labelled responder T cells isolated
from spleen and suppressor T cells generated by in vitro conversion as described. Responder and suppressor cells were added at a ratio of 1:1.
Suppressor cells were washed three times before addition to the assay.
doi:10.1371/journal.pone.0003302.g004
Figure 5. p38 MAP kinase inhibitor SB203580 specifically
inhibits the phosphorylation of p38 MAP kinase downstream
target MAPKAP2. A: CD4+CD252 T cells were cultured with TGF-
beta1 (2 ng/ml) and SB203580 (10 mM), SP600125 (10 mM), or PD89059
(50 mM) for 45 min. Control cells were cultured without TGF-beta1. B:
CD4+CD252 T cells were cultured for 4 hours with TGF-beta1 (2 ng/ml)
and SB203580 (10 mM). P-MAPKAP2, p-ERK, p-c-jun, p-Smad 3 and actin
were determined using Western blot. Results are representative of two
independent experiments.
doi:10.1371/journal.pone.0003302.g005
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The conversion of CD4+CD252 T cells into iTreg may be an
important mechanism in the dynamic regulation of immune
responses in vivo and the elucidation of its mechanisms may open
new targets for therapeutic intervention. We were therefore
interested in signaling pathways involved in peripheral Treg
generation. It has been previously shown that TGF-beta1 induces
Foxp3-expression in peripheral naı ¨ve CD4 T cells in vitro and in
vivo [3,4,22]. This conversion to iTreg seems to depend on the
main TGF-beta signaling pathway via activation of Smad 3 and
concomitant downregulation of inhibitory Smad 7 as well as
suboptimal TCR stimulation [17,24]. In addition to the Smad
cascade we have here analyzed p38 activation as an alternative
TGF-beta induced signaling pathway in Treg. We found an
increased activation of p38 MAP kinase in freshly isolated nTreg
as compared to CD4+CD252 T cells. This effect was at least
partially mediated via TGF-beta, as demonstrated in transgenic
CD4+CD25+ T cells with impaired TGF-beta signaling. In
addition to p38, the phosphorylation of Smad 2 and 3 was
upregulated and the expression of Smad 7 reduced in nTreg as
compared to CD4+CD252 T cells, giving support to the notion
that active TGF-beta signaling is required for Treg homeostasis in
vivo. These findings suggested that the p38 signaling pathway, in
addition to the Smad pathway, seemed to be spontaneously
activated in nTreg.
We then investigated, whether the p38 MAP kinase pathway
may be involved in the conversion of naive T cells into iTreg. P38
and Smad 3 were found to be spontaneously activated in freshly
isolated CD4+CD252 T cells, probably induced by the cell
isolation procedure. We therefore analyzed the cells after a resting
period of 4 hours. This may in part explain the differences
observed in comparison to previously published reports on the
effect of costimulation on p38 activation in T cell lines [25,26].
After cells had rested for four hours, TGF-beta was demonstrated
to induce phosphorylation of p38, whereas costimulation with
anti-CD3/CD28 had no effect on the activation of p38 at this time
point. At 16 hours of culture, costimulation alone was able to
Figure 6. P38 MAP kinase signaling is not required for the in vitro suppressive function of CD4+CD25+ T cells. Freshly isolated
CD4+CD252 T cells from spleen were labelled with CFSE and cultured for four days under CD3 stimulation (3 mg/ml) in the presence of allogeneic
CD32 spleen cells with or without CD4+CD25+ T cells freshly isolated from wild type mice, added at the indicated cell numbers
(responder+suppressor cells610
5). DMSO or SB203580 (10 mM) were added to the culture twice daily as indicated. CFSE dilution was measured
by flow cytometry after 4 days of coculture. Data are representative of four independent experiments.
doi:10.1371/journal.pone.0003302.g006
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mouse T cells [27]. The differences in timing and strength of
activation may relate to the fact that different time points were
analyzed and that complete medium supplemented with FCS,
which contains growth factors such as TGF-beta, were used in the
study by Zhang et al. [27].
We here report that TGF-beta1-induced conversion of CD252
T cells into Foxp3-expressing iTreg could be suppressed by the
addition of pharmacological inhibitors of p38. These findings are
in accordance with a recently published study reporting impaired
DC-induced conversion into iTreg after inhibition of p38 with
SB203580 [28] and suggest that p38 signaling is of functional
relevance for the generation of iTreg.
It has been reported that using high concentrations of
SB203580 kinases other than p38 may be inhibited as well
[21,23]. At the rather low concentrations used in our experiments
we could demonstrate specific inhibition of p38 downstream target
MAPKAP2 using SB203580. Interestingly, the phosphorylation of
Erk seemed to be increased by inhibiting p38, as has been reported
before [29]. The three MAP cascades may interact and the
inhibition of one may therefore enhance the activation of the other
as suggested for p38 and JNK [30]. In a similar manner, p38 and
Smad 3 signaling pathways may interact as it appeared that
inhibition of p38 augmented phosphorylation of Smad 3. This has
to our knowledge not been reported before and clearly requires
further investigation.
From the data presented (Figure 4) it may appear that
SB203580 affects CD25-expression. We therefore analyzed cell
activation markers and proliferation of T cells cultured in the
presence of the inhibitor. No differences in CD44-expression
(Figure S 2) or in cell numbers between cultures with or without
the inhibitor could be detected. Also, the proliferation of CD252
T cells was not affected by SB203580 (Figure 6), arguing against
an effect on overall T cell activation.
Pharmacological inhibition of p38 MAP kinase did not affected
the in vitro suppressive function of established nTreg. If confirmed
in vivo, it seems unlikely that the clinical use of p38 inhibitors may
lead to the induction of autoimmune disease. Indeed, such
inhibitors are being tested in clinical trials for the treatment of
autoimmune diseases, in which they appear to be safe [31].
However, our and the recently published [28] findings that such
p38 inhibitors may have the potential to interfere with the
peripheral generation of iTreg indicate that the treatment of
autoimmune diseases may not be the appropriate indication for
these inhibitors. It remains to be seen whether inhibition of the
p38 MAP kinase pathway in vivo may serve the therapy of chronic
infection or cancer.
In conclusion our findings indicate that signaling via p38 MAP
kinase, in addition to Smad 3 signaling is required for the in vitro
conversion of CD4+CD252 T cells into iTreg and thus may be
important for the regulation of the peripheral Treg pool. p38 MAP
kinase may be a potential therapeutic target for preventing the
induction of iTreg by malignant or infected cells in vivo. Although
there was no effect of p38 inhibition on the in vitro suppressive
capacity of nTreg, the effects and potential risks of p38 inhibition
in vivo require further study.
Supporting Information
Figure S1 Time course of p38 and Smad 3 activation in
CD4+CD252 T cells analyzed ex vivo . Freshly isolated cells
(4610
6) were cultured with or without TGF-beta1 (2 ng/ml) for
15 to 240 minutes. Cells were activated with plate bound anti-
CD3 mAb (2 mg/ml) and soluble anti-CD28 mAb (2 mg/ml) as
indicated. Smad 3 and p38 activation were measured using
Western blot.
Found at: doi:10.1371/journal.pone.0003302.s001 (6.30 MB TIF)
Figure S2 Representative CD442 and Foxp3-expression after
the in vitro conversion of CD4+CD252 T cells into iTreg in the
presence or absence of TGF-beta1 (2 ng/ml) and SB203580
(10 mM). Mean fluorescence intensity of CD44-FITC is given.
Found at: doi:10.1371/journal.pone.0003302.s002 (9.98 MB TIF)
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